Senseonics and Beta Bionics partner on AI-based pancreas

11 June 2018 (Last Updated June 11th, 2018 11:44)

Senseonics and Beta Bionics have signed an agreement to advance the development of the artificial intelligence (AI) based iLet Bionic Pancreas system. 

Senseonics and Beta Bionics have signed an agreement to advance the development of the artificial intelligence (AI) based iLet Bionic Pancreas system.

Under the alliance, Beta Bionics will integrate Senseonics’ Eversense continuous glucose monitoring (CGM) system into the bionic pancreas.

Eversense is designed as an implantable, long-term CGM device for continuous measurement of interstitial fluid glucose levels. The system then wirelessly transmits the readings to a smartphone app.

The purpose of adopting this system into the iLet is to enable real-time Eversense data to serve as a CGM option to drive the fully autonomous bionic pancreas.

Senseonics president and CEO Tim Goodnow said: “The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management.

“The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management.”

“We are pleased to be working with the Beta Bionics team as they advance a real breakthrough for people with diabetes.”

Beta Bionics is developing the dual-chamber, infusion pump iLet system to duplicate a biological pancreas via automatic and autonomous adjustment of insulin and glucagon dosing in order to meet the individual requirements of diabetes patients.

Beta Bionics president and CEO Ed Damiano said: “Senseonics has generated impressive clinical data demonstrating the remarkable accuracy of their Eversense CGM system and providing a categorically different CGM alternative for people with diabetes.

“We are excited to partner with Senseonics to help make the iLet Bionic Pancreas system a platform of choice for people with diabetes – one that will ultimately allow people to choose between multiple CGMs, to choose between multiple insulin types, and to choose glucagon.”